| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
|
| ln Vitro |
One of the most prevalent ingredients in ginseng is ginsenoside Rd. With an IC50 of 12.05±0.82, ginsenoside Rd significantly suppresses TNF-α-induced NF-κB transcriptional activity in HepG2 cells. Moreover, ginsenoside Rd dose-dependently reduced the expression of COX-2 and iNOS mRNA as well as iNOS promoter activity. HepG2 cells were exposed to substances like ginsenoside Rd at 0.1, 1, and 10 μM concentrations in order to identify nontoxic concentrations. The MTS assay was then used to assess the cells' viability. At concentrations as high as 10 μM, no compound showed any discernible cytotoxicity, indicating that cytotoxicity is not the cause of NF-κB inhibition [1]. One of ginseng's most prevalent ingredients, ginsenoside Rd, inhibits Ca2+ influx among other heart-protective mechanisms. The concentration-dependent reduction of ICa,L's peak amplitude (IC50=32.4±7.1 μM) is attributed to ginsenoside Rd [2]. With an IC50 of 58.0±4.5 μM, ginsenoside Rd inhibits the activity of CYP2D6 in human liver microsomes. With an IC50 of 78.4±5.3, 81.7±2.6, and 85.1±9.1, it has a weak inhibitory effect on the activities of CYP1A2, CYP3A4, and CYP2C9 in human liver microsomes. The inhibitory effect on CYP2A6 activity in human liver microsomes is even weaker, and the IC50 value exceeds 100μM[4].
|
|---|---|
| ln Vivo |
The primary substance that was identified from Gynostemma pentaphyllum, ginsenosides Rd, completely enhances the intestinal microenvironment and causes ApcMin/+ mice to develop resistance to polyposis. Ginsenoside Rd was administered to mice aged six weeks prior to the development of intestinal polyps. Changes in the mice's body weight, water and food intake were tracked. Throughout the trial, there was no weight loss in mice connected to Rb3/ginsenoside Rd. Furthermore, there were no alterations in the food and water intake of any of the treated mice. The quantity and size of polyps can be successfully decreased by ginsenoside Rd treatment [3].
|
| References |
|
| Additional Infomation |
Ginsenoside Rd is a ginsenoside found in Panax ginseng and Panax japonicus var. major that is (20S)-ginsenoside Rg3 in which the hydroxy group at position 20 has been converted to its beta-D-glucopyranoside. It has a role as a vulnerary, a neuroprotective agent, an apoptosis inducer, an anti-inflammatory drug, an immunosuppressive agent and a plant metabolite. It is a ginsenoside, a beta-D-glucoside and a tetracyclic triterpenoid. It is functionally related to a (20S)-ginsenoside Rg3.
Ginsenoside Rd has been reported in Panax pseudoginseng, Gynostemma yixingense, and other organisms with data available. See also: American Ginseng (part of); Panax notoginseng root (part of). |
| Molecular Formula |
C48H82O18
|
|---|---|
| Molecular Weight |
947.16
|
| Exact Mass |
946.55
|
| CAS # |
52705-93-8
|
| PubChem CID |
11679800
|
| Appearance |
White to off-white solid powder
|
| Density |
1.4±0.1 g/cm3
|
| Boiling Point |
1015.6±65.0 °C at 760 mmHg
|
| Melting Point |
207 °C(dec.)
|
| Flash Point |
568.0±34.3 °C
|
| Vapour Pressure |
0.0±0.6 mmHg at 25°C
|
| Index of Refraction |
1.611
|
| LogP |
3.24
|
| Hydrogen Bond Donor Count |
12
|
| Hydrogen Bond Acceptor Count |
18
|
| Rotatable Bond Count |
13
|
| Heavy Atom Count |
66
|
| Complexity |
1680
|
| Defined Atom Stereocenter Count |
25
|
| SMILES |
CC(=CCC[C@@](C)([C@H]1CC[C@@]2([C@@H]1[C@@H](C[C@H]3[C@]2(CC[C@@H]4[C@@]3(CC[C@@H](C4(C)C)O[C@H]5[C@@H]([C@H]([C@@H]([C@H](O5)CO)O)O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O)C)C)O)C)O[C@H]7[C@@H]([C@H]([C@@H]([C@H](O7)CO)O)O)O)C
|
| InChi Key |
RLDVZILFNVRJTL-IWFVLDDISA-N
|
| InChi Code |
InChI=1S/C48H82O18/c1-22(2)10-9-14-48(8,66-42-39(60)36(57)33(54)26(20-50)62-42)23-11-16-47(7)31(23)24(52)18-29-45(5)15-13-30(44(3,4)28(45)12-17-46(29,47)6)64-43-40(37(58)34(55)27(21-51)63-43)65-41-38(59)35(56)32(53)25(19-49)61-41/h10,23-43,49-60H,9,11-21H2,1-8H3/t23-,24+,25+,26+,27+,28-,29+,30-,31-,32+,33+,34+,35-,36-,37-,38+,39+,40+,41-,42-,43-,45-,46+,47+,48-/m0/s1
|
| Chemical Name |
(2S,3R,4S,5S,6R)-2-[(2R,3R,4S,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)-2-[[(3S,5R,8R,9R,10R,12R,13R,14R,17S)-12-hydroxy-4,4,8,10,14-pentamethyl-17-[(2S)-6-methyl-2-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyhept-5-en-2-yl]-2,3,5,6,7,9,11,12,13,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-yl]oxy]oxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol
|
| Synonyms |
Gypenoside VIII; Ginsenoside RD
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~105.58 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (2.64 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (2.64 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (2.64 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.0558 mL | 5.2789 mL | 10.5579 mL | |
| 5 mM | 0.2112 mL | 1.0558 mL | 2.1116 mL | |
| 10 mM | 0.1056 mL | 0.5279 mL | 1.0558 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
